PFIZER INC Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net
PFIZER INC (PFE) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net of $0 for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet · last filed 2026-08-04
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2026-06-28 was $0.00.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2026-03-29 was $0.00.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2025-06-29 was $0.00.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for the quarter ending 2025-03-30 was $0.00.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for fiscal 2025 was $0.00.
- PFIZER INC fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net for fiscal 2024 was $0.00.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net 12 month |
|---|---|---|---|
| 2026-06-28 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | |
| 2026-03-29 | $0.00 10-Q · filed 2026-05-05 | ||
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | ||
| 2025-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | |
| 2025-03-30 | $0.00 10-Q · filed 2026-05-05 | ||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |